Literature DB >> 25607833

Prolonged exposure vs eye movement desensitization and reprocessing vs waiting list for posttraumatic stress disorder in patients with a psychotic disorder: a randomized clinical trial.

David P G van den Berg1, Paul A J M de Bont2, Berber M van der Vleugel3, Carlijn de Roos4, Ad de Jongh5, Agnes Van Minnen6, Mark van der Gaag7.   

Abstract

IMPORTANCE: The efficacy of posttraumatic stress disorder (PTSD) treatments in psychosis has not been examined in a randomized clinical trial to our knowledge. Psychosis is an exclusion criterion in most PTSD trials.
OBJECTIVE: To examine the efficacy and safety of prolonged exposure (PE) therapy and eye movement desensitization and reprocessing (EMDR) therapy in patients with psychotic disorders and comorbid PTSD. DESIGN, SETTING, AND PARTICIPANTS: A single-blind randomized clinical trial with 3 arms (N = 155), including PE therapy, EMDR therapy, and waiting list (WL) of 13 outpatient mental health services among patients with a lifetime psychotic disorder and current chronic PTSD. Baseline, posttreatment, and 6-month follow-up assessments were made.
INTERVENTIONS: Participants were randomized to receive 8 weekly 90-minute sessions of PE (n = 53), EMDR (n = 55), or WL (n = 47). Standard protocols were used, and treatment was not preceded by stabilizing psychotherapeutic interventions. MAIN OUTCOMES AND MEASURES: Clinician-rated severity of PTSD symptoms, PTSD diagnosis, and full remission (on the Clinician-Administered PTSD Scale) were primary outcomes. Self-reported PTSD symptoms and posttraumatic cognitions were secondary outcomes.
RESULTS: Data were analyzed as intent to treat with linear mixed models and generalized estimating equations. Participants in the PE and EMDR conditions showed a greater reduction of PTSD symptoms than those in the WL condition. Between-group effect sizes were 0.78 (P < .001) in PE and 0.65 (P = .001) in EMDR. Participants in the PE condition (56.6%; odds ratio [OR], 3.41; P = .006) or the EMDR condition (60.0%; OR, 3.92; P < .001) were significantly more likely to achieve loss of diagnosis during treatment than those in the WL condition (27.7%). Participants in the PE condition (28.3%; OR, 5.79; P = .01), but not those in the EMDR condition (16.4%; OR, 2.87; P = .10), were more likely to gain full remission than those in the WL condition (6.4%). Treatment effects were maintained at the 6-month follow-up in PE and EMDR. Similar results were obtained regarding secondary outcomes. There were no differences in severe adverse events between conditions (2 in PE, 1 in EMDR, and 4 in WL). The PE therapy and EMDR therapy showed no difference in any of the outcomes and no difference in participant dropout (24.5% in PE and 20.0% in EMDR, P = .57). CONCLUSIONS AND RELEVANCE: Standard PE and EMDR protocols are effective, safe, and feasible in patients with PTSD and severe psychotic disorders, including current symptoms. A priori exclusion of individuals with psychosis from evidence-based PTSD treatments may not be justifiable. TRIAL REGISTRATION: isrctn.com Identifier: ISRCTN79584912.

Entities:  

Mesh:

Year:  2015        PMID: 25607833     DOI: 10.1001/jamapsychiatry.2014.2637

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  69 in total

1.  Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder.

Authors:  M Alexandra Kredlow; Kristin L Szuhany; Stephen Lo; Haiyi Xie; Jennifer D Gottlieb; Stanley D Rosenberg; Kim T Mueser
Journal:  Psychiatry Res       Date:  2017-01-04       Impact factor: 3.222

2.  Psychosis as a Barrier to the Expression of Sexuality and Intimacy: An Environmental Risk?

Authors:  José de Jager; Edward McCann
Journal:  Schizophr Bull       Date:  2017-01-03       Impact factor: 9.306

3.  Childhood Trauma Is Associated With Severity of Hallucinations and Delusions in Psychotic Disorders: A Systematic Review and Meta-Analysis.

Authors:  Thomas Bailey; Mario Alvarez-Jimenez; Ana M Garcia-Sanchez; Carol Hulbert; Emma Barlow; Sarah Bendall
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

4.  Posttraumatic Stress Disorder Symptoms and Social and Occupational Functioning of People With Schizophrenia.

Authors:  Lauren C Ng; Liana J Petruzzi; M Claire Greene; Kim T Mueser; Christina P C Borba; David C Henderson
Journal:  J Nerv Ment Dis       Date:  2016-08       Impact factor: 2.254

Review 5.  Should Posttraumatic Stress Be a Disorder or a Specifier? Towards Improved Nosology Within the DSM Categorical Classification System.

Authors:  Jeffrey Guina; Matthew Baker; Kelly Stinson; Jon Maust; Joseph Coles; Pamela Broderick
Journal:  Curr Psychiatry Rep       Date:  2017-08-15       Impact factor: 5.285

Review 6.  Treatments of Posttraumatic Stress Disorder in Civilian Populations.

Authors:  Lana Ruvolo Grasser; Arash Javanbakht
Journal:  Curr Psychiatry Rep       Date:  2019-02-08       Impact factor: 5.285

Review 7.  New avenues for treating emotional memory disorders: towards a reconsolidation intervention for posttraumatic stress disorder.

Authors:  Merel Kindt; Arnold van Emmerik
Journal:  Ther Adv Psychopharmacol       Date:  2016-05-01

8.  Neuropsychological predictors of response to cognitive behavioral therapy for posttraumatic stress disorder in persons with severe mental illness.

Authors:  Kim T Mueser; Susan R McGurk; Haiyi Xie; Elisa E Bolton; M Kay Jankowski; Weili Lu; Stanley D Rosenberg; Rosemarie Wolfe
Journal:  Psychiatry Res       Date:  2017-10-06       Impact factor: 3.222

9.  [Posttraumatic disorders in patients with schizophrenia spectrum disorders].

Authors:  I Schäfer; F J Eiroa-Orosa; K Schroeder; T Harfst; V Aderhold
Journal:  Nervenarzt       Date:  2015-07       Impact factor: 1.214

10.  Incidence and Risk Factors for Intensive Care Unit-related Post-traumatic Stress Disorder in Veterans and Civilians.

Authors:  Mayur B Patel; James C Jackson; Alessandro Morandi; Timothy D Girard; Christopher G Hughes; Jennifer L Thompson; Amy L Kiehl; Mark R Elstad; Mitzi L Wasserstein; Richard B Goodman; Jean C Beckham; Rameela Chandrasekhar; Robert S Dittus; E Wesley Ely; Pratik P Pandharipande
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.